Last edition
News about "phase 3 trial of PDP-716 to treat open angle glauc"
Sun Pharma Advanced Research Company Ltd. (SPARC) reported positive top-line results from its phase 3 trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension
Phase 3 Trial Of PDP-716 To Treat Open Angle Glauc | 14/05/2021 | By Darshana | 326
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members